Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
29 Agosto 2023 - 9:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq:
ARQT), an early commercial-stage biopharmaceutical company focused
on developing meaningful innovations in immuno-dermatology, today
announced the launch of The Cream That Can, the first commercial
direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the
treatment of plaque psoriasis, including intertriginous psoriasis
in adults and adolescents. The Cream That Can campaign invites
individuals with psoriasis to reimagine a steroid-free cream for
their psoriasis.
Watch The Cream That
Can Ad
A Media Snippet accompanying this announcement is
available by clicking on the image or link below:
Approximately 90% of people with plaque psoriasis are being
treated with topical treatments, with topical steroids considered
the first-line treatment option. Many topical treatments such as
high potency steroids have limitations that force patients and
their dermatologists to evaluate and make trade-offs between
efficacy, tolerability, and long-term use. The campaign aims to
strip the complexity out of topical management and leave
individuals to imagine what it would be like to have a steroid-free
treatment that could help clear skin.
“The Cream That Can helps make clear skin the hero. No matter
where plaque psoriasis may appear on the skin, whether in
hard-to-treat areas like knees and elbows, or sensitive areas like
the face and skin folds, ZORYVE is the cream that can help,” said
Ayisha Jeter, interim Chief Commercial Officer. “Now that more than
130 million commercial patients have access to ZORYVE, over 90% of
them without a prior authorization, and many physicians have
personal experience using ZORYVE, we believe the time is right to
build broader awareness of ZORYVE with consumers.”
The Cream That Can ad will air across many of the top on-demand
video streaming platforms.
ZORYVE, a once-daily, steroid-free phosphodiesterase-4 (PDE4)
inhibitor cream, provides rapid clearance, as early as Week 2
or 4, for both hard-to-treat areas, such as knees and elbows, as
well as sensitive areas, such as the face, intertriginous areas,
and genitalia.
In pivotal clinical studies for plaque psoriasis, approximately
40% of 576 adults and adolescents treated with ZORYVE achieved
significantly clearer skin at eight weeks, compared to only 6% of
305 individuals treated with a cream not containing the active
ingredient. Individuals applied ZORYVE once per day to treat mild
to severe plaque psoriasis—with affected areas including the
elbows, knees, face, intertriginous areas, and genitals.
ZORYVE is available by prescription only. For more information
about ZORYVE visit zoryve.com.
About ZORYVE®ZORYVE (roflumilast) cream 0.3% is
indicated for topical treatment of plaque psoriasis, including
intertriginous areas, in patients 12 years of age and older.
ZORYVE is for topical use only and not for ophthalmic, oral, or
intravaginal use.
IMPORTANT SAFETY INFORMATION The use of ZORYVE
is contraindicated in patients with moderate to severe liver
impairment (Child-Pugh B or C).
The most common adverse reactions (≥1%) include diarrhea (3%),
headache (2%), insomnia (1%), nausea (1%), application site pain
(1%), upper respiratory tract infection (1%), and urinary tract
infection (1%).
Please see full Prescribing Information.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is an early commercial-stage medical dermatology
company that champions meaningful innovation to address the urgent
needs of individuals living with immune-mediated dermatological
diseases and conditions. With a commitment to solving the most
persistent patient challenges in dermatology, Arcutis has a growing
portfolio that harnesses our unique dermatology development
platform coupled with our dermatology expertise to build
differentiated therapies against biologically validated targets.
Arcutis’ dermatology development platform includes a robust
pipeline with multiple clinical programs for a range of
inflammatory dermatological conditions including scalp and body
psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia
areata. For more information, visit www.arcutis.com or
follow Arcutis on LinkedIn, Facebook, and Twitter.
Forward-Looking StatementsArcutis cautions you
that statements contained in this press release regarding matters
that are not historical facts are forward-looking statements. These
statements are based on the Company’s current beliefs and
expectations. Such forward-looking statements include, but are not
limited to, statements regarding the potential for ZORYVE to
simplify disease management for care of plaque psoriasis; the
potential of real-world use results of roflumilast cream, as well
as the commercial launch of ZORYVE in plaque psoriasis. These
statements are subject to substantial known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Risks and uncertainties that may cause
our actual results to differ include risks inherent in our
business, reimbursement and access to our products, the impact of
competition and other important factors discussed in the "Risk
Factors" section of our Form 10-K filed with U.S. Securities and
Exchange Commission (SEC) on February 28, 2023, as well as any
subsequent filings with the SEC. You should not place undue
reliance on any forward-looking statements in this press release.
We undertake no obligation to revise or update information herein
to reflect events or circumstances in the future, even if new
information becomes available. All forward-looking statements are
qualified in their entirety by this cautionary statement, which is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Contacts:MediaAmanda Sheldon,
Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relationsemcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024